Evotec stock gains strongly as biotech news and SDAX momentum support the rebound

Evotec stock (ISIN DE0005664809) is staging a notable rebound on September 18, 2026, with the shares climbing more than 6 percent intraday on Xetra after recently touching a new 52-week and ten-year low at 2.77 EUR earlier in the week.

Evotec stock rebounds from multi-year lows

According to wallstreet-online on September 18, 2026, Evotec shares were recently quoted at 3.03 EUR, up 4.52 percent or 0.13 EUR compared with the previous trading day, after a gain of 2.55 percent the day before.

As finanzen.ch reports on September 18, 2026, Evotec SE is among the top performers in the SDAX, with the stock up 6.80 percent to 3.08 EUR and 498,084 shares traded at the home exchange, making it the most traded SDAX constituent at midday.

Earlier in the week, the stock had dropped to a 52-week low of 2.77 EUR on September 15, 2026, while the 52-week high was reached at 7.30 EUR on October 27, 2025, according to finanzen.ch, so even after the current rise the shares remain far below their historical peak.

Fresh project updates and sector visibility support sentiment

An important driver for the renewed interest in Evotec is a series of recent operational updates and increased visibility at sector conferences. As Aktiencheck highlights on September 18, 2026, Evotec Biologics, a subsidiary branded Just - Evotec Biologics, recently started a Phase 1 clinical trial for an antibody program commissioned by the United States Department of Defense targeting orthopox viruses.

According to Aktiencheck, Evotec also announced in early September a new research collaboration with Plectonic Biotech, combining its BiTco platform with Plectonic Biotech's LOGIBODY technology to develop T cell activating therapies against solid tumors, expanding its oncology pipeline.

The same overview notes that Evotec's management presented the company at the Morgan Stanley Healthcare Congress, aiming to strengthen its profile with institutional investors, which can help support the stock if the operational progress is matched by financial execution.

Analyst expectations underline current challenges

Despite the strong intraday rally, the fundamental backdrop remains demanding. As finanzen.ch reports, analyst consensus for the 2026 financial year points to an earnings per share of minus 1.297 EUR, indicating that the company is expected to remain loss-making for the year.

In a separate price-movement report on September 17, 2026, finanzen.ch notes that the stock traded at 2.87 EUR in the afternoon session, 3.49 percent above the 52-week low of 2.77 EUR, underscoring how closely the share price had approached that low before the current recovery.

Performance figures compiled by wallstreet-online show that, despite today's gain, Evotec shares have declined 38.62 percent over the past three months, 15.75 percent over the past month, and 47.13 percent since the beginning of the year, while the one-year performance stands at a negative 53.05 percent as of September 18, 2026.

Trading activity and index role in the SDAX

For investors following German small and mid cap indices, Evotec remains an important biotech component of the SDAX. As finanzen.ch states, the stock is currently one of the strongest gainers in the SDAX basket at midday on September 18, 2026, and is at the same time the most traded SDAX share during that period, with nearly half a million shares changing hands.

Earlier price snapshots from finanzen.ch show that the stock opened the Xetra session at 2.91 EUR on September 18, 2026, rose intraday to 2.98 EUR, and was quoted at 2.95 EUR, up 2.2 percent, in the morning, before the later push above 3 EUR recorded by other portals.

The recent move also comes after days of technical selling. As Aktiencheck comments, the stock had been heavily oversold before the rebound, which may have set the stage for a sharper recovery once positive news and stronger sector sentiment appeared.

Stock level and investor perspective

Per intraday Xetra data from September 18, 2026, Evotec stock most recently traded around the 3 EUR mark, approximately 6 to 11 percent above the 52-week low of 2.77 EUR recorded on September 15, 2026, but still far below the 52-week high of 7.30 EUR from October 27, 2025, so the current rally is a first recovery step rather than a full trend reversal.

More news and analyses on Evotec stock